Her2-BATS and Pembrolizumab in Metastatic Breast Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 29, 2017

Primary Completion Date

November 30, 2024

Study Completion Date

January 31, 2031

Conditions

Metastatic Breast Cancer

Interventions

DRUG

HER2 BATs with Pembrolizumab

8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab

Trial Locations (1)

Ashley Donihee, Charlottesville

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Virginia

OTHER

NCT03272334 - Her2-BATS and Pembrolizumab in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter